Citius Pharmaceuticals, Inc. CTXR · Stock Open Citius Pharmaceuticals, Inc. in new tab
Citius Pharmaceuticals, Inc. Analysis (CTXR)
Is Citius Pharmaceuticals, Inc. a good investment? Citius Pharmaceuticals, Inc. (CTXR) is currently trading at 0.4994 USD.
Earnings Schedule: Citius Pharmaceuticals, Inc. is expected to release its next earnings report on Dec. 17, 2026. The market consensus estimate for Forward EPS is -1.44.
Investor FAQ
Does Citius Pharmaceuticals, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Citius Pharmaceuticals, Inc.?
Citius Pharmaceuticals, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Dec. 17, 2026. The company currently has a trailing EPS of -1.75.
Company Profile
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
| Split Date | Split Ratio to 1 |
|---|---|
| June 9, 2017 | 1:15 |
Community Discussion